Impaired serotype-specific immune function following pneumococcal vaccination in infants with prior carriage-Reference-Cited by-同舟云学术

Impaired serotype-specific immune function following pneumococcal vaccination in infants with prior carriage

Published:2014-04 Issue:20 Volume:32 Page:2321-2327
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Licciardi Paul V.,Russell Fiona M.,Balloch Anne,Burton Robert L.,Nahm Moon H.,Gilbert Gwendolyn,Tang Mimi L.K.,Mulholland Edward K.

Funder

National Institute of Allergy and Infectious Diseases

NHMRC

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference37 articles.

1. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project;Johnson;PLoS Med,2010

2. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates;O’Brien;Lancet,2009

3. Pathogenesis, treatment, and prevention of pneumococcal pneumonia;van der Poll;Lancet,2009

4. Streptococcus pneumoniae colonisation: the key to pneumococcal disease;Bogaert;Lancet Infect Dis,2004

5. Human nasal challenge with Streptococcus pneumoniae is immunising in the absence of carriage;Wright;PLoS Pathog,2012

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunization with a whole cell vaccine reduces pneumococcal nasopharyngeal density and shedding, and middle ear infection in mice;Vaccine;2024-03

2. Therapeutic immunization with a whole cell vaccine reduces pneumococcal nasopharyngeal density, shedding, and middle ear infection in mice;2023-04-05

3. Australia’s Role in Pneumococcal and Human Papillomavirus Vaccine Evaluation in Asia-Pacific;Vaccines;2021-08-18

4. Immunogenicity and safety of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 2–5 years in China;Vaccine;2021-06

5. Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial;Vaccine: X;2021-04